Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranolazine: focusing on angina pectoris.

Peter A McCullough1

  • 1Department of Medicine, Divisions of Cardiology, Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. pmc975@yahoo.com

Drugs of Today (Barcelona, Spain : 1998)
|April 22, 2006
PubMed
Summary

Ranolazine, a novel anti-ischemic agent, shows promise for managing chronic stable angina refractory to conventional therapy. Its unique properties suggest potential for future use in acute coronary syndromes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.

European journal of heart failure·2019
Same author

The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.

Cardiorenal medicine·2019
Same author

The Promise of next generation sequencing micro RNA for the discovery of new targets in contrast induced acute kidney injury.

Annals of translational medicine·2019
Same author

Doppler-Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure.

Journal of the American Heart Association·2019
Same author

Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness.

Cardiorenal medicine·2019
Same author

Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review.

Reviews in cardiovascular medicine·2019

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic stable angina is a prevalent condition that poses management challenges, particularly in patients unresponsive to standard treatments.
  • Maximal revascularization may not always resolve symptoms in refractory angina.

Purpose of the Study:

  • To evaluate the potential of ranolazine as a therapeutic agent for chronic stable angina.
  • To highlight the unique anti-ischemic and electrophysiologic properties of ranolazine.

Main Methods:

  • The abstract discusses ranolazine, a late sodium channel inhibitor and partial fatty acid oxidation inhibitor.
  • Focuses on its pharmacological properties and clinical implications.

Main Results:

  • Ranolazine exhibits desirable anti-ischemic and electrophysiologic characteristics.

Related Experiment Videos

  • It is identified as a promising agent for difficult-to-manage angina.

    • Conclusions:

    • Ranolazine is poised to become a standard treatment for chronic stable angina.
    • Potential future applications in managing acute coronary syndromes are indicated.